美沙拉嗪在炎症性肠病应用中的不良反应分析  

Adverse reaction analysis of mesalazine in the treatment of inflammatory bowel disease

作　　者：张梦媛 刘怡婧 朱磊 ZHANG Meng-yuan;LIU Yi-jing;ZHU Lei(Department of Gastroenterology,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)

机构地区：[1]南京中医药大学附属医院消化内科,南京210029

出　　处：《中国新药杂志》2024年第15期1628-1632,共5页Chinese Journal of New Drugs

基　　金：江苏省中医药局科技发展项目(ZT202103,2022WTZX04);江苏省研究生实践创新计划资助项目(SJCX230863)。

摘　　要：炎症性肠病(inflammatory bowel disease, IBD)是一种原因不明的慢性非特异性肠道炎症性疾病,大多数患者需要长期服药。美沙拉嗪是临床治疗IBD的一线药物,属于5-氨基水杨酸(5-aminosalicylic acid, 5-ASA)衍生物,用于减轻肠道炎症反应的诱导和维持治疗,通常适应性良好,但另一方面,美沙拉嗪也暴露出一些不良反应如胃肠道不良反应、白细胞减少、肝功能损伤、胰腺炎、肺毒性及肾毒性等,涉及多个系统,并且不易与IBD自身并发症相区别。本文旨在总结美沙拉嗪不良反应及相应临床特征,为临床应用中正确识别及规避不良事件的发生提供参考,以达到保障治疗安全性的目的。Inflammatory bowel disease(IBD) is a chronic, non-specific inflammatory bowel disease of unknown pathogenesis, and most of the patients require long-term medication. Mesalazine, belonging to 5-aminosalicylic acid(5-ASA) derivatives, is a first-line drug for clinical treatment of inflammatory bowel disease, which is used as induction and maintenance therapy to reduce intestinal inflammatory responses. It is usually well adapted. However, mesalazine also exposed some adverse reactions such as gastrointestinal adverse reactions, leukopenia, hepatic impairment, pancreatitis, pulmonary toxicity and nephrotoxicity, which involve multiple systems and are uneasy to distinguish from the complications of IBD. The purpose of this article is to summarize the adverse reactions of mesalazine and their corresponding clinical characteristics, so as to provide reference for correctly identifying and avoiding the occurrence of adverse events in clinical application, in order to achieve the purpose of treatment safety.

关 键 词：美沙拉嗪 5-氨基水杨酸 炎症性肠病 不良反应 

分 类 号：R969.3[医药卫生—药理学]